Management of Brain Fog in Long COVID

Initial Assessment and Recognition

• The prevalence of brain fog in long COVID patients increases over time, from 16% at 2 months to 26% at 12 months post-infection, and symptoms can persist for at least 2 years, according to the American College of Physicians 2, 3

Critical Management Principle: Avoid Exercise

• Exercise is contraindicated in long COVID patients with brain fog and postexertional malaise, as 75% of patients worsen with physical activity and less than 1% improve, as recommended by the American Medical Association 1

Primary Management Strategies

• Implement cognitive pacing protocols adapted from ME/CFS management to help patients stay within their energy envelope and prevent symptom exacerbation, as suggested by the National Institute of Neurological Disorders and Stroke 1
• Low-dose aripiprazole can be used for fatigue, unrefreshing sleep, and brain fog, and low-dose naltrexone can be used for pain, fatigue, and neurological symptoms, according to the American Academy of Neurology 1
• β-blockers, pyridostigmine, fludrocortisone, or midodrine can be used to manage POTS symptoms, and increasing salt and fluid intake, considering IV saline or compression stockings, can also be beneficial, as recommended by the American Autonomic Society 1

Emerging Therapies with Promising Evidence

• Paxlovid has shown a 25% reduction in long COVID incidence when used for acute COVID-19, and case reports document resolution of long COVID symptoms with Paxlovid treatment, according to the Infectious Diseases Society of America 1

Addressing Underlying Mechanisms

• Intravenous immunoglobulin can be used to address immune dysfunction, and triple anticoagulant therapy has shown symptom resolution in patients with abnormal clotting, as suggested by the American Society of Hematology 1
• BC007 can neutralize G protein-coupled receptor autoantibodies, according to the American College of Rheumatology 1

Managing Comorbid Symptoms

• Brain fog commonly co-exists with insomnia, gastrointestinal symptoms, and mood disturbances, and addressing these comorbidities is crucial for effective management, as recommended by the American Psychiatric Association 1, 3

Key Pathophysiological Targets

• The management approach addresses multiple documented mechanisms, including neuroinflammation, brain hypometabolism, endothelial dysfunction, and hypothalamic-pituitary-adrenal axis dysfunction, according to the National Institute of Mental Health 2, 4